May 7, 2015 writer

TSO3 ANNOUNCES THE RESULTS OF THE VOTES AT THE ANNUAL AND SPECIAL MEETING OF THE SHAREHOLDERS

Québec City, May 7, 2015 – TSO3 Inc. (TSX: TOS) (“TSO3” or the “Corporation”) an innovator in sterilization technology for medical devices in healthcare settings, today announced that the nominees listed in the management proxy circular dated March 17, 2015, were elected as directors of TSO3 Inc. In addition, all other proposals submitted by management were approved.

Election of Directors

The shareholders were asked to provide their decision via a vote by proxy as part of TSO3Annual General Meeting of Shareholders, held on May 6, 2015 in Montréal. The detailed results of the vote are set out below.


Name
Votes for
% for
Votes against
% against
Withheld/
Abstain
% withheld
Germain Carrière
37,214,111
99.19
0.00
0.00
302,267
0.81
Pierre Désy
37,295,656
99.41
0.00
0.00
220,722
0.59
Jean Lamarre
37,332,011
99.51
0.00
0.00
184,367
0.49
W. Barry McDonald
16,002,835
42.66
0.00
0.00
21,513,543
57.34
Claude Michaud
37,347,111
99.55
0.00
0.00
169,267
0.45
Jean-Pierre Robert
37,267,611
99.50
0.00
0.00
188,766
0.50
Richard M. Rumble
37,320,046
99.48
0.00
0.00
196,332
0.52

*One director having been elected with fewer votes than a majority of the votes cast, the Board is proceeding in accordance with the majority voting policy of the Company.

Other Proposals

Appointment of Independent Auditors  38,914,934  99.94  0.00  0.00  24,646  0.00
Shareholders Rights Plan as modified  36,701,328  97.63  815,050  2.17 0  2.17
Stock Option Plan 31,133,893 82.99 6,382,485 17.01 0 17.01

Final voting results on all matters voted at the Annual Meeting of Shareholders held on May 6, 2015, will be filed on SEDAR (www.sedar.com) under the name TSO3.

About TSO3

Founded in 1998, TSO3’s activities encompass the sale, production, maintenance, research, development and licensing of sterilization processes, related consumable supplies and accessories for heat-sensitive medical devices. The Company designs products for sterile processing areas in the hospital environment that offer an advantageous replacement solution to other low temperature sterilization processes currently used in hospitals. It also offers services related to the maintenance of sterilization equipment and compatibility testing of medical devices with such processes.

For more information about TSO3, visit the Company’s Web site at www.tso3.com.

The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of any financing undertaken by TSO3) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other risks and uncertainties.

The TSX has neither approved nor disapproved the information contained herein and accepts no responsibility for it.

-30-

Back to Posts